There are currently 121 clinical trials in Fort Wayne, Indiana looking for participants to engage in research studies. Trials are conducted at various facilities, including Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne Medical Oncology and Hematology, Parkview Hospital Randallia and Parkview Regional Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Integrated Cancer Repository for Cancer Research
NCT02012699
Recruiting
The iCaRe2 is a multi-institutional resource created and maintained by the Fred & Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer... Read More
Gender:
All
Ages:
Between 19 years and 110 years
Trial Updated:
02/29/2024
Locations: Parkview Research Center, Fort Wayne, Indiana
Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control, Gastrointestinal Stromal Tumors, Central Nervous System Tumor, Central Nervous System Cancer
Register for Updates
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
NCT05856760
Recruiting
This is a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being on both stable RAASi and SGLT2 inhibitor treatment for at least 12 weeks prior to study entry
Gender:
All
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: Travere Investigational Site, Fort Wayne, Indiana
Conditions: Immunoglobulin A Nephropathy
Register for Updates
Hybrid Versus Non-Hybrid Endoscopic Submucosal Dissection for Colorectal Polyps (SHORT-ESD)
NCT05347446
Recruiting
This proposed trial will randomize 60 patients with a ≥20 mm large colorectal polyp to either undergo hybrid or non-hybrid ESD. For the primary comparison (hybrid vs non-hybrid ESD), the primary outcome will be procedure time. The study will further examine the safety and efficacy of hybrid ESD compared to non-hybrid ESD and investigate factors that may be associated with resection outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2024
Locations: Parkview, Fort Wayne, Indiana
Conditions: Colorectal Lesions
Register for Updates
ELUCIDATE FFRct Study
NCT06018194
Recruiting
The goal of this study is to evaluate the diagnostic accuracy of a novel plaque-based coronary CT angiography (CCTA) fractional flow reserve (FFRct) software device for the estimation of invasive fractional flow reserve (FFR). Researchers will compare the Elucid plaque-based FFRct analysis to invasively measured FFR in patients who have previously undergone CCTA and invasively assessed FFR.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: Parkview Health, Fort Wayne, Indiana
Conditions: Coronary Artery Disease
Register for Updates
Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
NCT03492151
Recruiting
The study schema is shown in Figure 4. (A) All patients referred to one of the participating academic centers for EUS evaluation of the PCL will be enrolled in the protocol if they satisfy inclusion criteria. Patient consent will be obtained during the clinic visit or prior to their EUS. EUS-guided nCLE imaging is first performed (B) followed by EUS-guided FNA and aspiration of cyst fluid. The cyst fluid is analyzed for CEA and cytology. As per institutional standard of care, the cyst fluid is a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: Parkview Hospital Randallia, Fort Wayne, Indiana
Conditions: Pancreatic Cyst
Register for Updates
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer
NCT05053152
Recruiting
This phase II trial tests whether relugolix and radiation therapy works to shrink tumors in patients with prostate cancer that has spread in a limited way to 1 to 5 other parts of the body (oligometastatic). Testosterone can cause the growth of prostate cancer cells. Relugolix lowers the amount of testosterone made by the body. This may help stop the growth of tumor cells that need testosterone to grow. Giving relugolix with radiation therapy may help lower the chance of prostate cancer growing... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Parkview Regional Medical Center, Fort Wayne, Indiana
Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
NCT06005974
Recruiting
This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors with AXIN1 or APC mutation.
Gender:
All
Ages:
55 years and above
Trial Updated:
02/02/2024
Locations: Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana
Conditions: AXIN1 Gene Mutation, APC Gene Mutation, Solid Tumor
Register for Updates
A Study of Infuse® Bone Graft With Mastergraft® Strip and Posterior Fixation for Posterolateral Fusion (PLF) Treatment of Multi-Level Degenerative Lumbosacral Spinal Conditions
NCT03118505
Recruiting
The purpose of this study is to obtain safety and effectiveness data on the investigational device for multi-level PLF procedures and determine the most appropriate rhBMP-2 dose for use in this indication. The study information may be used for a potential pivotal study design.
Gender:
All
Ages:
21 years and above
Trial Updated:
01/24/2024
Locations: Fort Wayne Orthopedics, Fort Wayne, Indiana
Conditions: Multi-Level Degenerative Lumbosacral Spinal Conditions
Register for Updates
ACL Bone Health and Loading Study
NCT04682392
Recruiting
The purpose of this study is to look at the effects of bone density on lower extremity loading mechanics using Blood Flow Restriction (BFR) to provide the control group for bone health. Hypothesis: The BFR group will have decreased bone mineral loss and improved functional performance compared to control group.
Gender:
All
Ages:
Between 16 years and 22 years
Trial Updated:
01/19/2024
Locations: Parkview Athletic Rehab, Fort Wayne, Indiana
Conditions: ACL Tear
Register for Updates
C-Brace Prospective Registry
NCT04640584
Recruiting
To gather prospective safety and effectiveness data for the C-Brace System following the standard of care.
Gender:
All
Ages:
All
Trial Updated:
01/09/2024
Locations: Prevail Prosthetics & Orthotics, Fort Wayne, Indiana
Conditions: Pareses, Lower Extremity
Register for Updates
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT05467891
Recruiting
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/04/2024
Locations: Parkview Research Center, Fort Wayne, Indiana
Conditions: Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Register for Updates
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/20/2023
Locations: Parkview Health, Fort Wayne, Indiana
Conditions: Breast Cancer
Register for Updates